The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (P-TRD)

COMPASS Pathways

Status and phase: Completed; Phase 2

Conditions: Treatment Resistant Depression

Treatments: Drug: Psilocybin

Study type: Interventional

Funder types: Industry

Identifiers

NCT03775200

COMP001

Details and patient eligibility

About

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression

Full description

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression - a dose-ranging study

Enrollment: 233 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of TRD

Exclusion criteria

• Other comorbidities

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

233 participants in 3 patient groups

Low dose

Experimental group

Description:

Low dose Psilocybin

Treatment:

Drug: Psilocybin

Medium dose

Experimental group

Description:

Medium dose Psilocybin

Treatment:

Drug: Psilocybin

High dose

Experimental group

Description:

High dose Psilocybin

Treatment:

Drug: Psilocybin